Subsynovial Connective Tissue and Carpal Tunnel Syndrome
Project Number5R01AR049823-02
Contact PI/Project LeaderAMADIO, PETER C
Awardee OrganizationMAYO CLINIC ROCHESTER
Description
Abstract Text
DESCRIPTION (provided by applicant): Carpal tunnel syndrome (CTS) is one of the most common causes of work-related disability in the US. The most common pathological finding is non-inflammatory synovial fibrosis and thickening, but whether this fibrosis is a cause of, or merely an associated finding with the compression neuropathy of the median nerve that is characteristic of CTS is unknown. This study will attempt to address this important issue by investigating the motion behavior, mechanical properties, and biological response of the synovium, and specifically the subsynovial connective tissue (SSCT), the gliding interface which links the tendons and synovium in the carpal tunnel. We hypothesize that activity-related damage may occur to the SSCT, resulting in fibrosis, diminished elasticity and increased gliding resistance in the carpal tunnel, setting up a vicious cycle of progressive injury that ultimately impairs permeability of the synovium, increases carpal tunnel pressure, and thereby causes the median neuropathy of CTS. To test this hypothesis, we propose three Specific Aims. Aim 1 is to describe the motion characteristics of the SSCT, by video, fluoroscopic, and ultrasound imaging, in normal human cadavers, patients with CTS, and in candidate animal models of CTS (dog and rabbit); in Aim 2, the mechanical properties and permeability of the SSCT in these same groups will be studied and compared. Aim 3 will characterize the histology and immunohistochemistry of the SSCT in these tissues; if this hypothesis regarding the etiology of CTS is correct, a biological basis for cumulative trauma as an etiology will be established for the first time for CTS. In addition, suitable animal models will be characterized for further experimental investigations of CTS. Finally, a new perspective would be provided, which could serve as a foundation for new therapies and prevention strategies for CTS.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
846
DUNS Number
006471700
UEI
Y2K4F9RPRRG7
Project Start Date
15-April-2003
Project End Date
31-March-2007
Budget Start Date
01-April-2004
Budget End Date
31-March-2005
Project Funding Information for 2004
Total Funding
$273,377
Direct Costs
$188,000
Indirect Costs
$85,377
Year
Funding IC
FY Total Cost by IC
2004
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$273,377
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AR049823-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AR049823-02
Patents
No Patents information available for 5R01AR049823-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AR049823-02
Clinical Studies
No Clinical Studies information available for 5R01AR049823-02
News and More
Related News Releases
No news release information available for 5R01AR049823-02
History
No Historical information available for 5R01AR049823-02
Similar Projects
No Similar Projects information available for 5R01AR049823-02